-
阿尔茨海默病(Alzheimer disease, AD)的特征性病理改变之一是大脑皮层纤维状的β淀粉样蛋白(β-amyloid, Aβ)的过度聚集, N-[11C]甲基-2-4′-甲基氨基苯基-6-羟基苯并噻唑(N-[11C]methyl-2-4′methylaminophenyl-6-hydroxybenzothiazole, 11C-PIB)能与细胞外和血管内纤维状的Aβ特异性结合[1], 但是与神经纤维缠结(neuronal fibrillary tangles, NFTs)或者路易体(Lewy body)结合不明显[1-2]。11C-PIB作为Aβ特异性的分子探针, 自2004年报道以来, 在AD及其相关性疾病的研究中得到广泛应用[3]。2010年AD协会国际年会发布了新的AD诊断标准[4], 提出AD是一个连续进展的疾病谱, 并将其分为临床前期AD、AD型轻度认知障碍(mild cognitive impairment, MCI)和AD型痴呆。本文主要对11C-PIB PET在不同时期AD中的应用进行综述, 及其在治疗中所起的作用等方面进行讨论。
11C-PIB PET在不同时期阿尔茨海默病中的研究进展
Application of 11C-PIB PET in different period of the Alzheimer disease
-
摘要: 阿尔茨海默病(AD)作为神经变性病, 起病隐袭, 早期诊断困难。β淀粉样蛋白(Aβ)沉积形成的老年斑是其特征性病理改变, 并且发生在疾病的早期阶段。N-[11C]甲基-2-4′-甲基氨基苯基-6-羟基苯并噻唑(11C-PIB)作为Aβ特异性的分子探针, 能够无创、实时、定量地监测脑内纤维状Aβ的变化。因此, 明确PIB在不同时期AD中的分布特点, 对AD的早期诊断、抗Aβ治疗的人群筛选以及疗效监测方面都具有重要意义。该文就近年来11C-PIB PET在不同时期AD中的应用作一综述。
-
关键词:
- 阿尔茨海默病 /
- 淀粉样β蛋白 /
- 正电子发射断层显像术
Abstract: Alzheimer disease (AD) is a neurodegenerative disease. It is difficult to make an early diagnosis because it is insidious onset. One of the neuropathological hallmarks of AD is the formation of senile plaques, which is composed of fibril amyloid β-protein (Aβ). And amyloid deposition is an early event on the path to dementia. N-[11C] methyl-2-4′-methylaminophenyl-6-hydroxybenzothiazole(11C-PIB) is a specific molecular probe of Aβ, which could monitor the change of fibril Aβ non-invasively, dynami-cally and quantitatively. In order to aid early diagnosis, screen the population for antiamyloid therapies and monitor the therapeutic effects, it is urgent to elucidate the PIB characteristics of distribution at different stage of AD. Therefore, the application of 11C-PIB PET in AD in the latest years will be summarized.-
Key words:
- Alzheimer′s disease /
- Amyloid beta-protein /
- Positron-emission tomography
-
[1] Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer′s disease. Brain, 2008, 131(Pt 6): 1630-1645. [2] Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci, 2007, 27(39): 10365-10371. doi: 10.1523/JNEUROSCI.0630-07.2007 [3] Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer′s disease with Pittsburgh Compound-B. Ann Neurol, 2004, 55(3): 306-319. doi: 10.1002/ana.20009 [4] Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011, 7(3): 257-262. doi: 10.1016/j.jalz.2011.03.004 [5] Raji CA, Becker JT, Tsopelas ND, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer′s disease with Pittsburgh Compound B. J Neurosci Methods, 2008, 172(2): 277-282. [6] Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer′s disease. Brain, 2008, 131(Pt6): 1630-1645. [7] Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol, 2009, 21(1): 117-128. [8] Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging, 2011, 32 Suppl 1: S20-36. [9] Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci, 2007, 27(23): 6174-6184. doi: 10.1523/JNEUROSCI.0730-07.2007 [10] Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med, 2004, 256(3): 183-194. [11] 程怀东, 汪凯.遗忘型轻度认知损害的早期诊断途径:从分子、影像到行为神经病学.中国现代神经疾病杂志, 2010, 10(2): 155-159. doi: 10.3969/j.issn.1672-6731.2010.02.003
[12] Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 2007, 130(Pt11): 2837-2844. [13] Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133(11): 3336-3348. doi: 10.1093/brain/awq277 [14] Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med, 2009, 360(22): 2302-2309. doi: 10.1056/NEJMoa0806142 [15] Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C-PiB and structural MRI provide complementary information in imaging of Alzheimer′s disease and amnestic mild cognitive impairment. Brain, 2008, 131(Pt3): 665-680. [16] Jacobs B, Schall M, Prather M, et al. Regional dendritic and spine variation in human cerebral cortex: a quantitative golgi study. Cereb Cortex, 2001, 11(6): 558-571. doi: 10.1093/cercor/11.6.558 [17] Attems J, Thal DR, Jellinger KA. The relationship between subcortical tau pathology and Alzheimer's disease. Biochem Soc Trans, 2012, 40(4): 711-715. [18] Tosun D, Schuff N, Mathis CA, et al. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain, 2011, 134(Pt4): 1077-1088. [19] Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol, 2008, 65(11): 1509-1517. doi: 10.1001/archneur.65.11.1509 [20] Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol, 2010, 67(1): 122-131. doi: 10.1002/ana.21843 [21] Price JL, Davis PB, Morris JC, et al. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging, 1991, 12(4): 295-312. doi: 10.1016/0197-4580(91)90006-6 [22] Vlassenko AG, Benzinger TL, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta, 2012, 1822(3): 370-379. doi: 10.1016/j.bbadis.2011.11.005 [23] Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011, 7(3): 280-292. doi: 10.1016/j.jalz.2011.03.003 [24] Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry, 2010, 67(6): 584-587. doi: 10.1016/j.biopsych.2009.08.024 [25] Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol, 2010, 9(4): 363-372. doi: 10.1016/S1474-4422(10)70043-0 [26] Alexander D, Robert P. Imaging amyloid in the human brain: a promising tool for improved early diagnosis and treatment monitoring in Alzheimer′s Disease. Open Nucl Med J, 2010, 2: 53-57.
计量
- 文章访问数: 1917
- HTML全文浏览量: 1124
- PDF下载量: 3